Manchester Grand Hyatt Hotel

Cutera, Inc. to Participate in Upcoming Investor Conferences

Retrieved on: 
Friday, November 10, 2023
General Health, Health, Medical Devices, Corporation, Manchester Grand Hyatt Hotel, Fireside chats, Conference, Dermatology, Hotel

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Taylor Harris, Chief Executive Office, and Greg Barker, Vice President of Corporate FP&A and Investor Relations, will participate in Fireside Chats at the following upcoming investor conferences:

Key Points: 
  • Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Taylor Harris, Chief Executive Office, and Greg Barker, Vice President of Corporate FP&A and Investor Relations, will participate in Fireside Chats at the following upcoming investor conferences:
    Stifel 2023 Healthcare Conference, 2:25pm ET on Wednesday, November 15, 2023, at the Lotte New York Palace Hotel, New York, NY
    Stephens Annual Investment Conference, 9:00am CT on Thursday, November 16, 2023, at the Grand Hyatt Hotel, Nashville, TN
    Piper Sandler Annual Healthcare Conference, 3:00pm ET on Wednesday, November 29, 2023, at the Lotte New York Palace Hotel, New York, NY
    The fireside chats will also be webcast and can be accessed from the Investor Relations section of Cutera’s website at http://www.cutera.com/ .
  • The webcast replay will be available at the same site approximately one hour after the end of the event.

Vinitaly International Academy Celebrates 6 New Italian Wine Ambassadors certified in Hong Kong

Retrieved on: 
Friday, December 1, 2023
Ambassador, Wine, Manchester Grand Hyatt Hotel, ITA, VIA, Student, Faculty, Social media, Exhibition, International Academy, Moon, Film industry, Tutoring, Nursing, Vinitaly, Hong Kong

VERONA, Italy, Dec. 1, 2023 /PRNewswire-PRWeb/ -- November 2023 marked an exciting return to Hong Kong for VIA. The Asia Pacific region has become an important epicenter for VIA, with 64 Italian Wine Ambassadors already certified there, including 11 in Hong Kong alone. Spreading Italian wine joy is a cornerstone of the program and VIA remains committed to an educational outreach that stretches to all corners of the globe. In this 26th Edition of the VIA Italian Wine Ambassador course, VIA Faculty member Sarah Heller MW taught the course in person at the Grand Hyatt Hotel in Hong Kong. Seven students successfully passed the rigorous exam; one student was already a certified Italian Wine Ambassador and six new Ambassadors joined the VIA community. Vinitaly Managing Partner Stevie Kim remarked: "It was a pleasure to hold the VIA course in Hong Kong once again, a location that is crucial to the Italian wine industry and dear to our hearts since our first course there in 2017."

Key Points: 
  • Vinitaly International Academy (VIA) hosted the 26th edition of its rigorous Italian Wine Ambassador Certification Course 27-29 November 2023 in Hong Kong, certifying 6 new Italian Wine Ambassadors.
  • The Asia Pacific region has become an important epicenter for VIA, with 64 Italian Wine Ambassadors already certified there, including 11 in Hong Kong alone.
  • The new Ambassadors are Nico Boulay of Hong Kong, Peter Bourke of Australia, Hei Tung Zita Chan of Hong Kong, Aubrey Lau of Hong Kong, Sean Ou of Singapore and Yongzhi Angie Tan of Hong Kong.
  • The VIA Hong Kong Students who passed the exam with VIA Faculty Sarah Heller, Italian Consul General in Hong Kong and Macau Carmelo Ficarra, and Trade Commissioner at ITA – Italian Trade Agency (Hong Kong office) Paola Bellusci.

Foresight Diagnostics Announces Six Presentations Highlighting the Utility of PhasED-Seq™ for Early and Accurate MRD Detection at the 65th American Society of Hematology Annual Meeting

Retrieved on: 
Wednesday, November 8, 2023
DLBCL, Lymphoma, Doctor of Philosophy, Health, PM, Society, ASH, Hematology, San Diego Convention Center, MRD, PET/CT, Manchester Grand Hyatt Hotel, Patient, Grande halle de la Villette, Neoplasm, Foresight, Medical imaging, Nightclub

The PhasED-Seq MRD platform is a ctDNA test that detects minimal residual disease (MRD) with higher levels of sensitivity and specificity compared to first-generation MRD technologies.

Key Points: 
  • The PhasED-Seq MRD platform is a ctDNA test that detects minimal residual disease (MRD) with higher levels of sensitivity and specificity compared to first-generation MRD technologies.
  • In patients with lymphomas, this could enable the earlier detection of residual disease in patients who are prone to relapse after first-line therapy.
  • Additionally, exploratory studies have demonstrated that PhasED-Seq's high sensitivity detected future relapse an average of 10 months sooner than imaging.
  • We are grateful to all the collaborators and presenters for their important work at the 2023 ASH Annual Meeting."

NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
TCE, Drug resistance, ROR1, Society, Hematology, CLL, Lymphoid neoplasms with plasmablastic differentiation, PK, Risk, Abstract, MCL, MRD, Trichloroethylene, Pharmacology, Autoregulation, CRS, Safety, AR, Manchester Grand Hyatt Hotel, Patient, Toxicity, Cerebral autoregulation, Mantle cell lymphoma, Therapeutic index, Birth control, Pharmaceutical industry

LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough immunotherapies, alongside an Autoregulation platform, today announces the online publication of two abstracts submitted to the American Society of Hematology Annual meeting, to be held December 9-12, 2023 in San Diego, USA.

Key Points: 
  • “We are pleased to announce our forthcoming oral presentation on the hematological arm of the NVG-111-01 Phase I clinical study (NCT04763083).
  • Building upon these achievements, we are advancing the development of NVG-111 into solid tumor indications,” said Professor Amit Nathwani, Founder and CEO of NovalGen.
  • This mitigates adverse events but also facilitates the administration of higher doses over extended durations, thereby expanding the therapeutic index.
  • NovalGen have shown that applying AR to TCEs does not affect the potency, but significantly reduces toxicity in pre-clinical models.

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Poster, NYSE, 65th Berlin International Film Festival, Doctor of Philosophy, Research, AM, Society, ASH, San Diego Convention Center, Diffuse large B-cell lymphoma, ADC, Abstract, Rituximab, Therapy, Manchester Grand Hyatt Hotel, Patient, Pharmaceutical industry, MD

LAUSANNE, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 9-12, 2023.

Key Points: 
  • LAUSANNE, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 9-12, 2023.
  • "We look forward to sharing insights from the growing body of research supporting the clinical utility of ZYNLONTA as a single agent and in combination with other treatments at the 65th ASH Annual Meeting,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
  • We look forward to additional details to be shared during the oral presentation.”
    Details of the oral presentation of the investigator-initiated study:
    Session: 623.
  • The abstracts are available through the ASH online meeting program.

Host Hotels & Resorts, Inc. Reports Third Quarter 2023 Results

Retrieved on: 
Wednesday, November 1, 2023
Golf, Adjustment, Insurance, Security (finance), Supplement, Tax, RevPAR, Wildfire, Food, Host, EBITDA, Share repurchase, GAAP, Grand Hyatt Atlanta in Buckhead, FFO, Comparable, Growth, Statistics, Total, NAREIT, Investment, Manchester Grand Hyatt Hotel, Hotel, Tourism, Video game, Fine chemical

BETHESDA, Md., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Host Hotels & Resorts, Inc. (NASDAQ: HST) (the “Company”), the nation’s largest lodging real estate investment trust (“REIT”), today announced results for third quarter of 2023.

Key Points: 
  • Additionally, comparable hotel results and statistics include adjustments for dispositions, acquisitions and non-comparable hotels.
  • See Hotel Operating Data for RevPAR results of the portfolio based on the Company’s ownership period without these adjustments.
  • During the third quarter of 2023, the $163 million loan to the buyer of the Sheraton Boston Hotel was repaid in full.
  • The Company paid a third quarter common stock cash dividend of $0.18 per share, an increase of $0.03, or 20%, over its second quarter dividend, on October 16, 2023 to stockholders of record on September 30, 2023.

Finalists Named for 2023 ISG Paragon Awards™ South America

Retrieved on: 
Wednesday, November 1, 2023
Telecommunications, Software, Networks, Internet, Consulting, Data Management, Professional Services, Technology, Paragon, Manchester Grand Hyatt Hotel, ISG, Organization, Research, Hyatt, Digital technology, Paulo, Sustainability, Consultant

Information Services Group ( ISG ) (Nasdaq: III ), a leading global technology research and advisory firm, today announced the finalists for the 2023 ISG Paragon Awards™ South America, which celebrate the ongoing transformation of sourcing industry partnerships through new approaches and technologies.

Key Points: 
  • Information Services Group ( ISG ) (Nasdaq: III ), a leading global technology research and advisory firm, today announced the finalists for the 2023 ISG Paragon Awards™ South America, which celebrate the ongoing transformation of sourcing industry partnerships through new approaches and technologies.
  • Here are the South America finalists for the 2023 awards:
    Environmental Sustainability: Recognizing outstanding positive impacts in one or more environmental sustainability fields for clients, consumers, communities and/or employees
    The ISG Paragon Awards™ South America, produced by ISG Events, recognize the innovative ways enterprises and providers are driving business success by leveraging digital technology and new operating models.
  • “Enterprises in South America seek partners to help them create hybrid, connected, autonomous, intelligent and effective organizations,” said Todd Lavieri, partner and president, ISG Americas and Asia Pacific.
  • “ISG research finds regional providers in South America are outpacing many larger global firms in helping clients adopt the technologies that can deliver transformative business outcomes.

HotSpot Therapeutics to Introduce First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
CBM, NF-κB, Non-Hodgkin lymphoma, IND, Biotechnology, Drug resistance, Multiple myeloma, Hotspot, Cell, Protein, Society, ASH, Lymphoid neoplasms with plasmablastic differentiation, Pharmacology, Bone marrow, Therapy, Manchester Grand Hyatt Hotel, Pharmaceutical industry, MALT1, Lymphoma

BOSTON, Nov. 2, 2023 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced it will present preclinical data from the Company's highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program in an oral presentation at the 2023 American Society of Hemotology (ASH) Annual Meeting, taking place December 9-12, 2023, in San Diego, CA.

Key Points: 
  • MALT1 is a component of the CARD11-BCL10-MALT1 (CBM) protein complex, which serves as a key regulator of NFkB signaling in cells, including B and T cells.
  • MALT1 is implicated in a range of hematological malignancies, including Non-Hodgkin's lymphoma, as well as other lymphomas and selected solid tumors.
  • Leveraging our proprietary Smart Allostery™ platform, HotSpot has developed first-in-class small molecules designed to selectively inhibit the scaffolding function of MALT1, a dominant driver of the NFkB pathway.
  • This oral presentation will describe the differentiated preclinical profile for HotSpot's scaffolding inhibitor, including the potential for an improved efficacy and safety profile versus traditional MALT1 inhibitors that target protease function.

Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Eli Lilly and Company, Experiment, NYSE, Reversibility, Prior, SLL, Use, LLY, Safety, Chronic lymphocytic leukemia, Mantle cell lymphoma, Covalent bond, Medication discontinuation, Society, ASH, Lymphocytosis, Tyrosine kinase, CLL, Poster, MCL, Lymphoid leukemia, Therapy, BTK, Manchester Grand Hyatt Hotel, Pharmaceutical industry, Vaccine, Hotel, Patient

INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.

Key Points: 
  • INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.
  • The presentations will provide updated, longer follow-up clinical safety and efficacy data for approved and investigational uses of pirtobrutinib from the ongoing Phase 1/2 BRUIN study in multiple B-cell malignancies.
  • In mantle cell lymphoma (MCL), an oral presentation will provide updated safety and efficacy results of pirtobrutinib in all patients, including those with biologically high-risk relapsed or refractory MCL.
  • Additionally, poster presentations will provide data on the clinical impact of pirtobrutinib following cBTKi treatment across other B-cell malignancies.

Stephens Announces 25th Annual Investment Conference in Nashville

Retrieved on: 
Wednesday, October 25, 2023
Thought Leadership, Finance, Public Relations, Investor Relations, Asset Management, Consulting, Banking, Communications, Professional Services, Research, EVP, Financial services, Consumer, Head, Manchester Grand Hyatt Hotel, Transport, Conference, Hyatt, Growth, Longevity, Health care, Telecommunications

Stephens, an independent financial services firm, announced today that its 25th Annual Investment Conference will be held in Nashville, Tennessee, from November 14th to the 16th at the Grand Hyatt Hotel.

Key Points: 
  • Stephens, an independent financial services firm, announced today that its 25th Annual Investment Conference will be held in Nashville, Tennessee, from November 14th to the 16th at the Grand Hyatt Hotel.
  • The Stephens Annual Investment Conference is invitation only.
  • “This is our 25th annual investment conference and we could not be more excited,” said Nik Fisken, EVP and head of Institutional Equities and Research at Stephens.
  • “The first Stephens Investment Conference in 1998 had less than 50 companies presenting and 150 total attendees while year’s conference will be roughly 10 times larger.